Literature DB >> 2140607

Discriminative stimulus properties of flesinoxan.

C E Ybema1, J L Slangen, B Olivier, J Mos.   

Abstract

Different groups of rats were trained to discriminate either 0.3 mg/kg of flesinoxan (N = 13) or 0.1 mg/kg of 8-OH-DPAT (N = 7) from saline in a two-lever operant drug discrimination task using a fixed ratio 10 schedule of reinforcement. Once trained, animals in both groups displayed a dose-related decrease in discriminative performance upon administration of lower doses of the drug used in training. In generalization tests, flesinoxan generalized to 8-OH-DPAT in 8-OH-DPAT-trained animals and 8-OH-DPAT substituted for flesinoxan in flesinoxan-trained animals. Buspirone substituted partially for both the flesinoxan and the 8-OH-DPAT cue. The results of the present study indicate similarity between the discriminative stimulus effects of flesinoxan and the stimulus produced by the 5-HT1A agonist 8-OH-DPAT. These results, coupled with the finding that flesinoxan has a significant affinity and selectivity for 5-HT1A binding sites, suggest that the stimulus effects of flesinoxan are mediated by a 5-HT1A mechanism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2140607     DOI: 10.1016/0091-3057(90)90358-o

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  3 in total

1.  The discriminative stimulus properties of buspirone involve dopamine-2 receptor antagonist activity.

Authors:  H J Rijnders; J L Slangen
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

2.  Flesinoxan shows antidepressant activity in a DRL 72-s screen.

Authors:  A van Hest; M van Drimmelen; B Olivier
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Discriminative stimulus properties of 8-OH-DPAT: relationship to affinity for 5HT1A receptors.

Authors:  D J Sanger; H Schoemaker
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.